Research funding

Research & development at EUROIMMUN is supported by the European Regional Development Fund (ERDF).

At our branch in Dassow (Mecklenburg-Vorpommern) a project is funded which focuses on peptide-based diagnoses of food allergies. The central task of this project is the identification of molecular target structures of the allergy-specific antibodies based on clinically characterised patient sera. These amino acid sequences are then applied as antigens in a novel serological test system for the diagnosis of food allergies. Differentiation, prognosis and therapy of food allergies shall be helped by the characterisation of the epitopes. The peptide-based multiparameter test shall enable diagnosis of severe symptoms and replace risky provocation tests.


The project EUROPathology System (EPS) encompasses the development of new methodical approaches for histopathology. EPS will incorporate all important steps from production of tissue sections to evaluation and documentation of results. The system will be composed of modules designed for each phase of the workflow, from sample entry to issuing and archiving of results.


A research project with different medical research institutions in the German federal state of Mecklenburg-Vorpommern focuses on the development of new test systems for diagnostics of endocrinological autoimmune diseases. These diseases are caused by chronic inflammatory reactions of the immune system against body-own structures, which affect hormones and their activities.
In order to enable detection of the disease-associated autoantibodies, sensitive and reliable test systems shall be developed, which can be automatically processed on random-access instruments, thus representing a fast and standardisable detection method. They should be applied for early detection and disease monitoring and provide information on beginning sequelae. The performance evaluation will be made with respect to currently established test methods.
The risk of particular diseases increases with the concentration, the number and the specificity of different autoantibodies. Autoantibody screening, which only becomes practicable by automation, allows early recognition of a disease and prevention of complications. Moreover, sensitive detection of autoantibodies could also provide information on the disease course.
In addition, alternatives to autoantibody diagnostics shall be explored. The detection of particular autoantigens in patient serum shall be established. The aim is to investigate whether the autoantigens might be more suitable for diagnostics and course monitoring than autoantibodies.

Back to top